The Phase 2, open label study is designed to examine the effect of BBP-589 on wound healing and various systemic endpoints and to evaluate the long-term safety and tolerability of the drug candidate. The study plans to enroll six patients who will receive doses of BBP-589 intravenously in two regimens over 18 weeks, followed by 12 weeks of observation after completion of dosing to assess the durability of wound healing and other efficacy endpoints. To learn more about the BBP-589 Phase 2 clinical trial, please visit www.clinicaltrials.gov.